Clinical Trial Update: Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating dual immune checkpoint inhibitors in PD-L1-positive stage IV non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Intergroupe Francophone de Cancerologie Thoracique | Conditions: Non-Small Cell Lung Cancer Metastatic | Phase 3 | Status: COMPLETED